Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Zelenectide pevedotin (BT8009)
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 73
- Registration Number
- NCT06933329
Study to Assess Clinical Activity of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Zelenectide pevedotin (BT8009)
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 66
- Registration Number
- NCT06840483
- Locations
- πΊπΈ
Siteman Cancer Center, Saint Louis, Missouri, United States
πΊπΈCompass Oncology - Rose Quarter Cancer Center, Portland, Oregon, United States
πΊπΈSCRI Oncology Partners, Nashville, Tennessee, United States
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 956
- Registration Number
- NCT06225596
- Locations
- πΊπΈ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
πΊπΈVirginia K. Crosson Cancer Center at St. Jude Medical Center, Fullerton, California, United States
πΊπΈUniversity of California - Irvine Medical Center, Orange, California, United States
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 200
- Registration Number
- NCT05163041
- Locations
- πΊπΈ
State University of Iowa, Iowa City, Iowa, United States
πΊπΈColumbia University Irving Medical Center, New York, New York, United States
πΊπΈUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
- Conditions
- Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative NeoplasmsHormone Receptor Positive, HER2-low NeoplasmsBreast NeoplasmsNon-Small-Cell Lung NeoplasmsOvarian NeoplasmAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 329
- Registration Number
- NCT04561362
- Locations
- π«π·
Centre Eugene Marquis, Rennes, France
π«π·Institut Bergonie, Bordeaux, France
π«π·Institut Gustave Roussy, Villejuif, France
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
- Conditions
- Triple Negative Breast CancerUrothelial CancerOvarian CancerNon-small Cell Lung CancerAdvanced Solid Tumor Historically Known for High EphA2 ExpressionHead and Neck CancerGastric/Upper Gastrointestinal Cancer
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 288
- Registration Number
- NCT04180371
- Locations
- πΊπΈ
Sarah Cannon and HCA Research Institute, Nashville, Tennessee, United States
πΊπΈCalifornia Cancer Associates for Research and Excellence, Inc., Encinitas, California, United States
πΊπΈUniversity of California, San Diego (UCSD) - Medical Center, La Jolla, California, United States